Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2
|
| pubmed:dateCreated |
1995-6-23
|
| pubmed:abstractText |
Chromosomal beta-lactamase production is considered to be the most important resistance mechanism of Pseudomonas aeruginosa against beta-lactams. Recently we have detected serum and sputum antibodies against P. aeruginosa chromosomal beta-lactamase (a beta ab), using immunoblotting techniques. In this study we have developed an enzyme-linked-immunosorbent assay to measure serum a beta ab response in 124 cystic fibrosis patients in a cross-sectional study and in 54 cystic fibrosis patients in a longitudinal study. The a beta ab response occurred after a median of 3 years following onset of chronic infection and was significantly higher (P < 0.0002) in patients chronically infected with resistant strains than in those from whom resistant strains were occasionally isolated. The a beta ab levels correlated (r = 0.51, P = 0.0001) with the number of beta-lactam courses. A 14 fold increase in a beta ab levels occurred during the 14 year period covered by the longitudinal study. The results of this study show that a beta ab to P. aeruginosa is a specific marker for resistance development of P. aeruginosa to beta-lactams.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Feb
|
| pubmed:issn |
0305-7453
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
35
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
295-304
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:7759393-Adolescent,
pubmed-meshheading:7759393-Adult,
pubmed-meshheading:7759393-Antibodies, Bacterial,
pubmed-meshheading:7759393-Biological Markers,
pubmed-meshheading:7759393-Child,
pubmed-meshheading:7759393-Child, Preschool,
pubmed-meshheading:7759393-Chromosomes, Bacterial,
pubmed-meshheading:7759393-Cross-Sectional Studies,
pubmed-meshheading:7759393-Cystic Fibrosis,
pubmed-meshheading:7759393-Drug Resistance, Microbial,
pubmed-meshheading:7759393-Humans,
pubmed-meshheading:7759393-Infant,
pubmed-meshheading:7759393-Longitudinal Studies,
pubmed-meshheading:7759393-Middle Aged,
pubmed-meshheading:7759393-Pseudomonas Infections,
pubmed-meshheading:7759393-Pseudomonas aeruginosa,
pubmed-meshheading:7759393-Reproducibility of Results,
pubmed-meshheading:7759393-Sensitivity and Specificity,
pubmed-meshheading:7759393-beta-Lactamases,
pubmed-meshheading:7759393-beta-Lactams
|
| pubmed:year |
1995
|
| pubmed:articleTitle |
Antibodies against Pseudomonas aeruginosa chromosomal beta-lactamase inpatients with cystic fibrosis are markers of the development of resistance of P. aeruginosa to beta-lactams.
|
| pubmed:affiliation |
Institute of Medical Microbiology and Immunology, University of Copenhagen, Denmark.
|
| pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|